SEC Form 4 · accession 0000899243-16-012467
KERYX BIOPHARMACEUTICALS INC · KERX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Greg Madison
Officer — President and CEO · Director
Period of report
Jan 28, 2016
Accepted (ET)
Feb 1, 2016 · 6:57 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001114220
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jan 28, 2016 | A | 153,750 | $0.00 | A | 264,570 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F3 | $3.35 | Jan 28, 2016 | A | 307,500 | A | Jan 28, 2017 | Jan 28, 2026 | Common Stock | 307,500 | 307,500 | D |
Explanation of responses
- F1The 153,750 shares are restricted common stock, with one-third of the 153,750 shares vesting on January 28, 2017 and one-twelfth vesting on each of April 28, 2017, July 28, 2017, October 28, 2017, January 28, 2018, April 28, 2018, July 28, 2018, October 28, 2018, and January 28, 2019.
- F2Includes 201,333 shares of restricted stock.
- F3The options vest according to the following schedule: one-third of the 307,500 options will vest on January 28, 2017 and one-twelfth will vest on each of April 28, 2017, July 28, 2017, October 28, 2017, January 28, 2018, April 28, 2018, July 28, 2018, October 28, 2018, and January 28, 2019.